Is booze good for you? Industry backs long-term study
It may be the most palatable advice you will ever get from a doctor: Have a glass of wine, a beer or a cocktail every day, and you just might prevent a heart attack and live longer.
But the mantra that moderate drinking is good for the heart has never been put to a rigorous scientific test, and new research has linked even modest alcohol consumption to increases in breast cancer and changes in the brain.
That has not stopped the alcoholic-beverage industry from promoting the alcoholis-good-for-you message by supporting scientific meetings and nurturing budding researchers in the field.
Now the National Institutes of Health is starting a $100 million clinical trial to test for the first time whether a drink a day really does prevent heart attacks. And guess who is picking up most of the tab?
Five companies that are among the world’s largest alcoholic beverage manufacturers — Anheuser-Busch InBev, Heineken, Diageo, Pernod Ricard and Carlsberg — have so far pledged $67.7 million to a foundation that raises money for the National Institutes of Health, said Margaret Murray, the director of the Global Alcohol Research Program at the National Institute on Alcohol Abuse and Alcoholism, which will oversee the study.
The decision to let the alcohol industry pay the bulk of the cost has raised concern among researchers who track influence-peddling in science.
“Research shows that industry-sponsored research almost invariably favors the interests of the industry sponsor, even when investigators believe they are immune from such influence,” said Marion Nestle, a professor of nutrition and food studies at New York University who is the author of several books on the topic, including “Food Politics: How the Food Industry Influences Nutrition and Health.”
The international effort to study the benefits and risks of alcohol will recruit nearly 8,000 volunteers age 50 or older at 16 sites around the world, starting at medical centers in the United States, Europe, Africa and South America. Participants will be randomly assigned to quit alcohol altogether or to drink a single alcoholic beverage of their choice every day.
The trial will follow them for six years to see which group — the moderate drinkers or the abstainers — has more heart attacks, strokes and deaths. The study organizers conceded that it would be a challenge to recruit volunteers, who will not know in advance whether they will be assigned to abstain or be required to drink. Those in the drinking group will be partly reimbursed for the cost of the alcohol.
George F. Koob, the director of the alcohol institute, said the trial will be immune from industry influence and will be an unbiased test of whether alcohol “in moderation” protects against heart disease.
“This study could completely backfire on the alcoholic beverage industry, and they’re going to have to live with it,” Koob said.
But Koob, like many of the researchers and academic institutions playing pivotal roles in the trial, has had close ties to the alcoholic-beverage industry. From 1999 to 2003, Koob served on the medical advisory council of the Alcoholic Beverage Medical Research Foundation, now called the Foundation for Alcohol Research, an industry group that also provided him research grants of up to $40,000 a year between 1990 and 1994, said John Bowersox, a spokesman for the NIH’s alcohol institute.
Indeed, many of those involved in the study have financial links — either personally or through an institution — to alcohol industry money.
The principal investigator of the new study, Dr. Kenneth J. Mukamal, a Harvard associate professor of medicine and a visiting scientist at the School of Public Health, said he has never received funding from the industry. Mukamal, who has published dozens of papers on the health benefits of alcohol consumption, said he was not aware that alcohol companies were supporting the trial financially.
“This isn’t anything other than a good old-fashioned NIH trial,” he said. “We have had literally no contact with anyone in the alcohol industry in the planning of this.”
A spokeswoman for Pernod Ricard, one of the beverage firms that has pledged money to pay for the study, said company officials signed on because they were impressed by the ambitious scale of the trial.
“We’ve never seen a study of such scope or caliber,” said Sandrine Ricard, deputy director for corporate social responsibility for Pernod Ricard. She noted that the businesses will “have no say” in the research and that they “don’t want to have any say.”
Gemma R. Hart, vice president for communications at Anheuser-Busch, said the company has been investing heavily in efforts to promote responsible drinking and has an interest in generating research to guide evidence-based approaches to changing consumer behavior.
Though the company is helping to fund the trial, “Our role is limited entirely to the funding we provided,” Hart said. “We have no role in the study. We will learn the outcome of the study when everybody else does”
Scientists first floated the hypothesis that moderate alcohol consumption is good for one’s health nearly 100 years ago, when a Johns Hopkins scientist published a graph showing that modest drinkers lived longer than not only heavy drinkers, but also abstainers.
Critics of the alcohol hypothesis say moderate drinking might just be something that healthy people tend to do, not something that makes people healthy.
The new trial defines moderate drinking as one serving a day, defined as 12 ounces of beer, 5 ounces of wine or 1.5 ounces of distilled spirits. The definition is significantly lower than what has typically been considered a moderate level of drinking for men, which has long been defined as up to two servings a day. Moderate drinking for women has been defined as one serving a day.
The recruits will be men and women 50 or older, all of whom either have cardiovascular disease or are at high risk for developing it. Problem drinkers and individuals who have never consumed alcohol will be ineligible, as will be certain women at high risk for breast cancer and people with certain medical conditions. Investigators have not determined how they will verify that participants are sticking to their regimens of one drink a day or no alcohol at all.
The study has limitations. Adverse events related to alcohol, including car accidents, major falls, heart conditions and new cancer diagnoses will be tracked, but the study is not large enough or long enough to detect an increase in breast cancer.